Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorFederal University of Rio Grande do Norte (UFRN)-
Autor(es): dc.creatorFenley, Juliana de C.-
Autor(es): dc.creatorde Barros, Patrícia P.-
Autor(es): dc.creatorCarmo, Paulo H. F. do-
Autor(es): dc.creatorGarcia, Maíra T.-
Autor(es): dc.creatorRossoni, Rodnei D.-
Autor(es): dc.creatorJunqueira, Juliana C.-
Data de aceite: dc.date.accessioned2025-08-21T21:30:27Z-
Data de disponibilização: dc.date.available2025-08-21T21:30:27Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-10-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/cimb44110364-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/249358-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/249358-
Descrição: dc.descriptionCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental candidiasis. For this, clinical strains of C. albicans were subjected to in vitro and in vivo treatments with ATV or DRV. As a result, ATV and DRV exhibited antifungal activity against fungal cells at 512 μg/mL, reduced the viability and biomass of biofilms, and inhibited filamentation of C. albicans. In addition, these HIV-PIs downregulated the expression of SAP2 and BRC1 genes of C. albicans. In an in vivo study, prophylactic use of ATV and DRV prolonged the survival rate of Galleria mellonella larvae infected with C. albicans. Therefore, ATV and DRV showed activity against C. albicans by reducing cell growth, biofilm formation, filamentation, and expression of virulence genes. Furthermore, ATV and DRV decreased experimental candidiasis, suggesting the repurposing of HIV-PIs as antifungal treatments for C. albicans infections.-
Descrição: dc.descriptionDepartment of Biosciences and Oral Diagnosis Institute of Science and Technology São Paulo State University (Unesp), São Paulo-
Descrição: dc.descriptionMulticampi School of Medical Sciences Federal University of Rio Grande do Norte (UFRN), Rio Grande do Norte-
Descrição: dc.descriptionDepartment of Biosciences and Oral Diagnosis Institute of Science and Technology São Paulo State University (Unesp), São Paulo-
Formato: dc.format5379-5389-
Idioma: dc.languageen-
Relação: dc.relationCurrent Issues in Molecular Biology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectatazanavir sulfate-
Palavras-chave: dc.subjectCandida albicans-
Palavras-chave: dc.subjectdarunavir-
Palavras-chave: dc.subjectHIV-
Palavras-chave: dc.subjectprotease inhibitors-
Palavras-chave: dc.subjectvirulence factors-
Título: dc.titleRepurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.